Acumen shares surge 20.79% intraday on ALTITUDE-AD trial extension progress and BTIG price target upgrade to $7.

Acumen Pharmaceuticals (ABOS) surged 20.79% intraday following BTIG’s upgrade, which raised its price target to $7 from $4 while maintaining a Buy rating. The move aligns with the company’s recent clinical progress, including dosing the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for Alzheimer’s, reinforcing momentum toward a late-2026 data readout. Insider sales tied to tax obligations were deemed routine and not indicative of negative sentiment. Analyst optimism and advancing clinical milestones likely drove the sharp intraday rally.